Publications
Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.
Semaglutide in Type 2 Diabetes With Chronic Kidney Disease at High Risk of Progression: Real-World Clinical Practice
Clin Kidney J 2022;15(8);1593-600 doi: 10.1093/ckj/sfac096
In this real-world study, patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) treated with semaglutide significantly improved glycaemic control and decreased weight.
Effect of Semaglutide and Liraglutide in Individuals With Obesity or Overweight Without Diabetes: A Systematic Review
Ther Adv Chronic Dis 2022;13:1-14 doi: 10.1177/20406223221108064
This systematic literature review found liraglutide and semaglutide led to clinically relevant (≥5%) weight loss in 48.2–88.7% of obese or overweight adults without diabetes.
Data on the effects of liraglutide and semaglutide in diabetes are well-known, but therapeutic outcomes in obese or overweight individuals without diabetes have not been summarised. This systematic review aimed to evaluate their effects in this population, and 18 studies representing 10,938 patients were included.
Efficacy of Subcutaneous Semaglutide Compared to Placebo For Weight Loss in Obese, Non-diabetic Adults: A Systematic Review & Meta-Analysis
Int J Clin Pharm 2022; online ahead of print DOI: 10.1007/s11096-022-01428-1
This systematic review and meta-analysis validates the clinical efficacy of semaglutide for the treatment of obesity in adults without T2D. There is substantial evidence for clinicians to consider modification to their management obese population.
Research of the effect of semaglutide on weight loss has largely focused on T2D, and no meta-analyses in non-diabetic individuals have been conducted to date.
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Circulation 2022;145:575–85 doi: 10.1161/CIRCULATIONAHA.121.055459
In this analysis by Shaman et al., semaglutide and liraglutide offered kidney-protective effects in patients with type 2 diabetes, especially those with pre-existing chronic kidney disease.
Semaglutide Once a Week in Adults With Overweight or Obesity, With or Without Type 2 Diabetes in an East Asian Population (STEP 6): A Randomised, Double-Blind, Double-Dummy, Placebo Controlled, Phase 3a Trial
Lancet Diabetes Endocrinol 2022;10:193–206. doi.org/10.1016/S2213-8587(22)00008-0
In this Phase 3a trial in an east Asian population, semaglutide 2.4 mg QW was shown to have superior and clinical meaningful reductions in bodyweight versus placebo, as well as greater reductions in abdominal visceral fat.
Efficacy and Safety of Once-Weekly Semaglutide in Adults With Overweight Or Obesity: A Meta-Analysis
Endocrine. 2022;75(3):718–24 doi: 10.1007/s12020-021-02945-1
Semaglutide QW was found to be superior to placebo in percentage change and absolute change in body weight. It also led to significant increases in proportions of patients achieving categorical weight reduction targets.
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
JAMA 2022;327(2):138–50 doi:10.1001/jama.2021.23619
Among adults with overweight or obesity without diabetes, QW SC semaglutide compared with QD SC liraglutide – added to counselling for diet and physical activity – resulted in significantly greater weight loss at 68 weeks.
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
N Engl J Med 2019;381:841–51 DOI 10.1056/NEJMoa1901118
In the PIONEER 6 trial, the cardiovascular risk profile of oral semaglutide was noninferior to placebo over 83 weeks.